FDA Approves Mysterious 'Field Generator Positioning Devices' for Brains
Published Date: 11/26/2025
Rule
Summary
The FDA has officially classified the field generator positioning device as a low-risk, Class I device, making it easier and faster for patients to get access to this helpful technology. This change reduces red tape for manufacturers without compromising safety or effectiveness. The new classification took effect on November 26, 2025, but has been in place since July 10, 2020, so no new costs or delays are expected.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier patient access to device
If you are a patient, the FDA has classified the field generator positioning device as Class I (general controls), and says this will enhance patients' access by reducing regulatory burdens. The final order is effective November 26, 2025, and the classification was applicable on July 10, 2020.
Manufacturers face lower premarket burden
If you manufacture or import this device, FDA placed the field generator positioning device in Class I (general controls) and states devices in this type are exempt from premarket notification (510(k)) under section 510(l)(1), except when the device is of substantial importance in preventing impairment of human health or presents a potentially unreasonable risk. FDA says this classification reduces regulatory burdens; the final order is effective November 26, 2025 and was applicable on July 10, 2020.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2025-21217, Medical Devices; Gastroenterology-Urology Devices; Classification of the Anchored Esophageal Sheath
The FDA is officially classifying the anchored esophageal sheath as a Class II medical device with special safety rules. This change helps make sure the device is safe and effective while making it easier for patients to get access to this helpful technology. The new rules took effect on November 26, 2025, and could reduce some regulatory hurdles for manufacturers.
Next: 2025-21242, Extending Deadline for Debtor To Request a Waiver
The VA is giving veterans more time—up to one year instead of 180 days—to ask for a waiver on debts related to benefits. This change, effective January 26, 2026, helps reduce stress by giving veterans extra breathing room to handle their debt issues. It doesn’t cost veterans extra money but makes the process friendlier and fairer.